Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strong near-term catalyst stack: FDA approved AUVELITY for agitation associated with dementia due to Alzheimer's disease on 2026-04-30/05-01, Q1 2026 product revenue rose 57% YoY to $191.2M, NDA submitted for AXS-12, SUNOSI patent settlement extended protection, and the stock is up about 33% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Persistent Losses ⢠Rising Leverage ⢠Cash Burn AXSM's strong revenue growth and 94% gross margins are outweighed by persistent losses, cash burn, rising leverage, equity dilution, and an exceptionally high valuation.
Price Behavior
Key Price Behavior Insights: ⢠Wide trading range ⢠Rebound faded ⢠Neutral momentum Support Level: $204â206 (stronger: $198.50â202.80) Resistance Level: $214â216 (major: $220.75) AXSM was range-bound last month; watch $204â206 support and $214â216 resistance, with a break above $220.75 bullish and a loss of $204 bearish.
Sentiment & News
Key News Insights: ⢠BlackRock Stake ⢠Phase 3 Launch ⢠CNS Data Axsome's institutional backing, Phase 3 expansion, and new CNS data support growth prospects despite post-earnings share weakness.
AI Summary
AXSM is now a high-expectation commercial execution investment: sustained AUVELITY growth and a successful Alzheimer's-agitation launch could unlock powerful operating leverage, but its premium valuation, >80% AUVELITY revenue concentration, cash burn, and potential dilution leave little margin for a growth slowdown. Investors should look for accelerating portfolio diversification and shrinking free-cash-flow losses before adding aggressively.
Description
Axsome Therapeutics is a U.S.-based biopharmaceutical company developing treatments for central nervous system disorders. Its late-stage pipeline includes a depression candidate (AXS-05) with additional trials in Alzheimer's-related agitation and prior smoking cessation data, a migraine treatment that completed Phase III testing (AXS-07), and Phase III programs for narcolepsy (AXS-12) and fibromyalgia (AXS-14). The company has a research collaboration with Duke University and was founded in 2012 in New York City.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| May 5 | May 12 | AXSM | Axsome Therapeutics, Inc. | Strong near-term catalyst stack: FDA approved AUVELITY for agitation associated with dementia due to Alzheimer's disease on 2026-04-30/05-01, Q1 2026 product revenue rose 57% YoY to $191.2M, NDA submitted for AXS-12, SUNOSI patent settlement extended protection, and the stock is up about 33% over 21 trading days. | Closed | +0.4% |
| Jan 1 | Jan 8 | AXSM | Axsome Therapeutics, Inc. | Axsome Therapeutics is a hot idea with key upcoming FDA priority review of AXS-05 and NDA filing for AXS-12, strong Q3 revenue growth, and robust technical momentum. Despite operating losses and governance risks, its near-term regulatory catalysts provide potential for significant short-term price appreciation. | Closed | -8.3% |